Abstract

For a successful application – we recommend the following guidelines

  • The maximum number of characters in your abstract should be under 2500 characters to be able to post it
  • Please take care of your case sensitivity, especially regarding your name because we will use this data to create your conference certificates.
  • You won’t be able to modify your abstract after it has been submitted.
  • We do not accept Reviews or Meta-Studies
  • Only abstracts in the English language will be reviewed
  • Remember to check your grammar and orthography
  • Make sure to structure your abstract as follows:
    • Title:  Should be a relatively unambiguous sentence describing the research for example: “HIV-1 transgene expression in rats causes oxidant stress and alveolar epithelial barrier dysfunction”
    • Background:  In the background you should describe the current state of scientific progress regarding your field. It should also contain the aim of your research and why it is important.
    • Methods:  This section should contain the basic means employed to conduct your research.
    • Results:  Here only the most important results should be presented. Be specific. Use numbers to make your point if and avoid vague expressions like “very much” or “small” if possible.
    • Conclusion:  Within this section you should interpret the meaning of the results regarding your initial aims. What are the implications of the research conducted? Resembles your project a new and interesting path worth to be followed or do results show that initial assumptions lead to a dead end? Are your results potentially generalizable or specific to a particular case?
You can find an example for a good Abstract below  
(Source: http://www.ncbi.nlm.nih.gov/pubmed/21490140# )
TITLE: Maternal supplementation with docosahexaenoic acid during pregnancy does not affect early visual development in the infant: a randomized controlled trial.
BACKGROUND: The docosahexaenoic acid (DHA) intake of pregnant women is lower than estimates of the DHA accretion by the fetus, and recommendations were made to increase the DHA intake of pregnant women.
OBJECTIVE:The objective of this study was to determine whether the supplementation of pregnant women with DHA improved the visual acuity of infants at 4 mo.METHODS: We conducted a blinded assessment of a subset of healthy, full-term infants born to women enrolled in a double-blind, randomized controlled trial called the DHA for Maternal and Infant Outcomes (DOMInO) trial. Women were randomly assigned to consume DHA-rich fish-oil capsules (≈800 mg DHA/d in the treatment group) or vegetable oil capsules (control group) from midpregnancy to delivery. The primary outcome was the sweep visual evoked potential (VEP) acuity at 4 mo. The VEP latency at 4 mo was a secondary outcome.
RESULTS: Mean (±SD) VEP acuity did not differ between treatment and control groups [treatment group: 8.37 ± 2.11 cycles per degree (cpd), n = 89; control group: 8.55 ± 1.86 cpd, n = 93; P = 0.55]. VEP latencies also did not differ between groups. Irrespective of the group, maternal smoking in pregnancy was independently associated with poorer VEP acuity in the infant.
CONCLUSIONS: DHA supplementation in women with singleton pregnancies does not enhance infant visual acuity in infants at 4 mo of age. Visual acuity in infancy is adversely associated with maternal smoking in pregnancy. This trial was registered at www.anzctr.org.au as ACTRN12606000327583. The DOMInO trial was registered at www.anzctr.org.au as ACTRN12605000569606.
  •  Initially we will only judge your abstract on formal grounds
  • Because of our submission form you won’t be able to format your font which we will take into account
  • If the abstract passes this procedure it will be forwarded to our scientific board and evaluated with regards to its content
  • Authors of abstracts found to be promising by our Board will be invited to the conference in September.

We are looking forward to receive your Abstract and all the exciting research and ideas within it!